Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
HN-2301 in Scleroderma, Systemic: NCT06801119 Clinical Landscape Report 2026
15 October 2026
NCT06801119 clinical landscape for Scleroderma, Systemic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NN-3201 in Uveal Melanoma: NCT06805825 Clinical Landscape Report 2026
15 October 2026
NCT06805825 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Capecitabine in Neoplasms: PACTR202502755674107 Clinical Landscape Report 2026
15 October 2026
PACTR202502755674107 clinical landscape for Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Posaconazole in Triple Negative Breast Cancer: NCT06802757 Clinical Landscape Report 2026
15 October 2026
NCT06802757 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TNG-456 in Adenocarcinoma: NCT06810544 Clinical Landscape Report 2026
15 October 2026
NCT06810544 clinical landscape for Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dubodencel in Glioblastoma Multiforme: NCT06805305 Clinical Landscape Report 2026
15 October 2026
NCT06805305 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gboxin in Diffuse midline glioma, point mutation K27M in histone H3: NCT06806228 Clinical Landscape Report 2026
15 October 2026
NCT06806228 clinical landscape for Diffuse midline glioma, point mutation K27M in histone H3: endpoints, sponsor, phase, geography, readouts, asset context a…
9 min read
Rituximab biosimilar (Shanghai Institute of Biological Products) in Large B-cell lymphoma: NCT06811272 Clinical Landscape Report 2026
15 October 2026
NCT06811272 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GLYCAR T cell therapy(Baylor College of Medicine) in Glioblastoma: NCT06815432 Clinical Landscape Report 2026
15 October 2026
NCT06815432 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab in Glioblastoma Multiforme: NCT06816927 Clinical Landscape Report 2026
15 October 2026
NCT06816927 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TARLATAMAB-DLLE in Olfactory Esthesioneuroblastoma: NCT06814496 Clinical Landscape Report 2026
15 October 2026
NCT06814496 clinical landscape for Olfactory Esthesioneuroblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludeoxyglucose F-18 in High grade glioma: NCT06815029 Clinical Landscape Report 2026
15 October 2026
NCT06815029 clinical landscape for High grade glioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.